Business Context and Reporting Period
This Form 8-K Current Report was filed by Ekso Bionics Holdings, Inc. on April 18, 2016. The report discloses significant corporate governance changes, specifically the appointment of a new Chief Executive Officer and Board member.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data disclosed relates to executive compensation adjustments.
- CEO Annual Salary: Increased to $350,000.
- Annual Bonus Eligibility: Up to 40% of base salary, contingent on operational or financial milestones.
Material Changes
The primary material change is the leadership transition effective immediately on April 18, 2016:
- Appointment: Thomas Looby was appointed President and Chief Executive Officer.
- Board Election: Mr. Looby was elected to the Board of Directors.
- Background: Mr. Looby had served as President and Interim CEO since February 2016 and previously held roles as Chief Commercial Officer and Chief Marketing Officer at the company since 2014.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of specific risks or contingencies. It notes that the press release regarding this appointment is furnished under Regulation FD and is not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for additional strategic context not included in the 8-K.
- Review the Company's 2015 Form 10-K for the complete details of Mr. Looby's prior compensation structure.
- Confirm the specific operational and financial milestones established by the Board for the new CEO bonus plan.